Four main lines outline the investment path of pharmaceutical stocks

The General Office of the State Council issued the "Guiding Opinions on Pilot Projects for Comprehensive Reform of Urban Public Hospitals," and proposed to further expand the pilots for comprehensive reform of urban public hospitals in 2015. By 2017, the comprehensive pilot reform of urban public hospitals will be fully implemented. The core contents include: First, the mechanism for remedying medical problems is broken. We will strive to achieve a 30% reduction in the proportion of drug use in public hospitals in the city (excluding Chinese Herbal Pieces) in 2017; a decrease in the number of medical materials in medical income (excluding pharmaceuticals) to 20 yuan or less; and second, deepen the reform of medical insurance payment methods. . The establishment of pay-based pay-as-you-give, pay-per-head, pay-per-service, and other compound payment methods. The medical insurance payment reform in 2015 will cover all public hospitals in the region and gradually cover all medical services. Third, strengthen the construction of regional medical and health information platform. Before the end of 2015, all government hospitals in Grade 2 or above and more than 80% of primary medical and health institutions in the administrative region were connected to regional platforms. 60% of primary health care institutions and superior hospitals establish a telemedicine information system; Fourth, promote social forces to participate in public hospital reforms. In cities where public hospitals are rich in resources, some public hospitals may choose to introduce social capital for pilot reforms.

In this regard, market participants pointed out that the "Opinions" need to focus on the promotion of the separation of medicines, the proportion of controlled drugs, the reform of medical insurance payments, the promotion of regional medical information platform construction, and grading diagnosis and treatment. The implementation of individual stocks should be beneficial to the relevant medical stocks, which can be actively laid out.

According to statistics from the Market Research Center, yesterday's medical bio-sector performed well. There were 149 stocks whose share price rose on that day, accounting for 84.66%. Among them, up to 30 daily limit stocks, excluding 10 new stocks listed since this year, the rest of daily limit individual stocks are: Tonghua Dongbao, Taiji Group, Guangji Pharmaceutical, Laimei Pharmaceutical, Hokuriku Pharmaceutical, Hipro, Kang Zhi Pharmaceutical, Shangrong Medical, Dahuanong, Hanyu Pharmaceutical, Qianshan Pharmaceutical Machinery, Ruikang Pharmaceutical, Jincheng Pharmaceutical, David Medical, Chutian Technology, Wuwu Biological, Taicheng Pharmaceutical, Jiuqiang Biological, Liuzhou Pharmaceutical, and Jia South Technology. In addition, Jinyu Group, Jianghua Pharmaceutical, Hansen Pharmaceutical, Winbond Yingtai, Fuan Pharmaceutical, Tibet Pharmaceutical, Zixin Pharmaceutical, Shanghai Kaibao, Fangsheng Pharmaceutical, Libang Instrument, Guanxi Bio, Diving Individuals such as medical stocks also rose more than 8%.

According to statistics from the Market Research Center, yesterday's pharmaceutical bio-sector showed a large net inflow of capital, and accumulated net inflows of large single funds were 608 million yuan. Among them, there were 81 stocks with large net capital inflows over 10 million yuan, and Renhe Pharmaceutical (2.22 billion yuan), Harbin Pharmaceuticals (2.02 billion yuan), Hualan Biotech (126 million yuan), Zixin Pharmaceutical ( The net inflows of seven major stocks, including 117 million yuan), Kangyuan Pharmaceutical (108 million yuan), Jiaying Pharmaceutical (106 million yuan), and Shangrong Medical (104 million yuan), all exceeded 100 million yuan.

CICC's analysis of the "Guiding Opinions" believes that there are four major investment opportunities in the following areas: First, retail pharmacies and pharmaceutical distribution industries: In the context of family medicine, outpatient pharmacies are gradually escaping from hospitals and the outflow of prescription drugs is a major trend, promising GPOs. The development of new models such as hospital supply chain, the recommendation of Shanghai Pharmaceuticals and Sinopharm Co., Ltd. are the same, and it is recommended to pay attention to Jiashitang, ordinary people, Yifeng pharmacy, and one heart. Secondly, Chinese Herbal Medicine, Chinese Herbal Formula Granule Industry: Chinese Herbal Medicine Pieces and Chinese Herbal Formula Particles are not included in the survey of hospital medicines, nor are they affected by the hospital bidding price cuts. The industry maintains high growth, and Hongyin Pharmaceutical and China Resources Sanjiu are recommended. Third, medical information, Internet medical: "Opinions" clearly put forward quantitative indicators, regional medical informatization and telemedicine will accelerate development, recommend Lepu medical, it is recommended to pay attention to Hainan Haishu. Finally, the Private Hospital Group: The "Opinions" call for further expansion of public hospital reform pilots to encourage private capital to participate in restructuring. Outstanding private hospital groups that have accumulated rich experience will benefit. Recommended Eye Ophthalmology, it is recommended to pay attention to general medical care.